Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

BCL6-IN-6

Catalog No. T60008 Copy Product Info
Purity: 98.90%
😃Good
BCL6-IN-6 is an inhibitor of Bcl-6 and can be used in studies about diffuse large B-cell lymphoma. BCL6-IN-6 blocks the interaction of Bcl-6 with its corepressors and dose-dependently reactivates Bcl-6 target genes.

BCL6-IN-6

Copy Product Info
😃Good
Catalog No. T60008

BCL6-IN-6 is an inhibitor of Bcl-6 and can be used in studies about diffuse large B-cell lymphoma. BCL6-IN-6 blocks the interaction of Bcl-6 with its corepressors and dose-dependently reactivates Bcl-6 target genes.

BCL6-IN-6
Cas No. 2408882-54-0
TargetMol | Customer service
Customer service consultation
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$41In StockIn Stock
5 mg$103In StockIn Stock
10 mg$179In StockIn Stock
25 mg$285In StockIn Stock
50 mg$407In StockIn Stock
100 mg$547In StockIn Stock
In stock · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:98.90%
Appearance:Solid
Color:Yellow
Contact us for more batch information

Resource Download

Product Introduction

BCL6-IN-6 AI Summary
BCL6-IN-6 exhibits significant bioactivities, including inhibition of recombinant human C-terminal GST-tagged BCL6 BTB domain with an IC50 of 470.0 nM and showing binding affinity to the human BCL6 BTB domain. It demonstrates antiproliferative activity across various human cell lines, with IC50 values between 920.0 nM to 3250.0 nM, as well as cytotoxicity with IC50 values ranging from 8130.0 nM to 32400.0 nM. Additionally, it induces apoptosis in SUDHL4 cells, displaying both early and late apoptotic effects at varying concentrations. In vivo, it inhibits germinal center formation in NP-CGG immunized C57BL/6 mice, affecting splenic GC B cells and the proportion of Tfh cells at a 10 mg/kg dose. The compound shows antiproliferative and antitumor activity against BCL-6 dependent human SU-DHL-4 cells, including those xenografted in mice, and results in increased mRNA expression of CD69, CXCR4, and ATR. Furthermore, BCL6-IN-6 is metabolically stable in human liver microsomes with a half-life greater than 1.0 hour and demonstrates high protein binding in human plasma, with a fraction unbound of 0.076..
Note: Summary generated by AI. Data source: ChEMBL
Bioactivity
Description
BCL6-IN-6 is an inhibitor of Bcl-6 and can be used in studies about diffuse large B-cell lymphoma. BCL6-IN-6 blocks the interaction of Bcl-6 with its corepressors and dose-dependently reactivates Bcl-6 target genes.
Chemical Properties
Molecular Weight522.64
FormulaC27H31FN6O2S
Cas No.2408882-54-0
SmilesCOc1cc(Nc2nc(ncc2F)N2C[C@H](C)N[C@H](C)C2)ccc1NC(=O)c1ccc(s1)C1=CCCC1
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: < 5.23 mg/mL (10 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM1.9134 mL9.5668 mL19.1336 mL95.6681 mL
5 mM0.3827 mL1.9134 mL3.8267 mL19.1336 mL
10 mM0.1913 mL0.9567 mL1.9134 mL9.5668 mL
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy BCL6-IN-6 | purchase BCL6-IN-6 | BCL6-IN-6 cost | order BCL6-IN-6 | BCL6-IN-6 chemical structure | BCL6-IN-6 formula | BCL6-IN-6 molecular weight